Mar 05, 2014
GSK and J&J have released a new AIDS drug to transform the outlook of the disease. New pharmaceutical candidates will be needed for proper promotion of these products to various markets.
Feb 27, 2014
Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts.
Feb 25, 2014
According to the Centers for Disease Control, more than two million people come down with antibiotic-resistant infections annually, and at least 23,000 die because their treatment can't stop the infection. In addition, the pipeline for new antibiotic
Jan 14, 2014
Artificial bone marrow may be used to reproduce hematopoietic stem cells. A prototype has now been developed by scientists of KIT, the Max Planck Institute for Intelligent Systems, Stuttgart, and Tübingen University (Germany).
Dec 09, 2013
Pfizer Inc. has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK's trametinib combined with Pfizer's palbociclib (PD-0332991) in a Phase I/II study in patients with advanced/metastatic melanoma.
Nov 19, 2013
A study published in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure.
Nov 11, 2013
The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team has identified a family of enzymes.
Nov 04, 2013
The Bayer Group continued its positive business momentum in the third quarter of 2013, with substantial contributions from the Life Science businesses HealthCare and CropScience
Nov 01, 2013
A team of 22 scientists from 11 research institutes led by Professor Bazbek Davletov, now at the University of Sheffield, created and characterised a new molecule that was able to alleviate hypersensitivity to inflammatory pain.
Oct 31, 2013
Pfizer Inc. reported financial results for third-quarter 2013. Reported revenues decreased $310 million, or 2%, which reflects an operational decline of $38 million, or less than 1%, and the unfavorable impact of foreign exchange of $272 m